| Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19 RT Eastman, JS Roth, KR Brimacombe, A Simeonov, M Shen, S Patnaik, ... ACS central Science 6 (5), 672-683, 2020 | 951 | 2020 |
| Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria RT Eastman, DA Fidock Nature Reviews Microbiology 7 (12), 864-874, 2009 | 681 | 2009 |
| Drug-resistant malaria: molecular mechanisms and implications for public health I Petersen, R Eastman, M Lanzer FEBS letters 585 (11), 1551-1562, 2011 | 397 | 2011 |
| Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue SH Adjalley, GL Johnston, T Li, RT Eastman, EH Ekland, AG Eappen, ... Proceedings of the National Academy of Sciences 108 (47), E1214-E1223, 2011 | 340 | 2011 |
| Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics MH Gelb, WC Van Voorhis, FS Buckner, K Yokoyama, R Eastman, ... Molecular and biochemical parasitology 126 (2), 155-163, 2003 | 181 | 2003 |
| Piperaquine Resistance Is Associated with a Copy Number Variation on Chromosome 5 in Drug-Pressured Plasmodium falciparum Parasites RT Eastman, NV Dharia, EA Winzeler, DA Fidock Antimicrobial agents and chemotherapy 55 (8), 3908-3916, 2011 | 161 | 2011 |
| Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation RT Eastman, FS Buckner, K Yokoyama, MH Gelb, WC Van Voorhis Journal of lipid research 47 (2), 233-240, 2006 | 151 | 2006 |
| Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate AM Lisewski, JP Quiros, CL Ng, AK Adikesavan, K Miura, N Putluri, ... Cell 158 (4), 916-928, 2014 | 146 | 2014 |
| Recent highlights in antimalarial drug resistance and chemotherapy research DA Fidock, RT Eastman, SA Ward, SR Meshnick Trends in parasitology 24 (12), 537-544, 2008 | 138 | 2008 |
| Deep learning identifies synergistic drug combinations for treating COVID-19 W Jin, JM Stokes, RT Eastman, Z Itkin, AV Zakharov, JJ Collins, ... Proceedings of the National Academy of Sciences 118 (39), e2105070118, 2021 | 120 | 2021 |
| High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations BT Mott, RT Eastman, R Guha, KS Sherlach, A Siriwardana, P Shinn, ... Scientific reports 5 (1), 13891, 2015 | 115 | 2015 |
| A Specific Inhibitor of PfCDPK4 Blocks Malaria Transmission: Chemical-genetic Validation KK Ojo, RT Eastman, RSR Vidadala, Z Zhang, KL Rivas, R Choi, JD Lutz, ... The Journal of infectious diseases 209 (2), 275-284, 2014 | 101 | 2014 |
| Trypanosoma cruzi Inactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV WC Van Voorhis, LK Barrett, RT Eastman, R Alfonso, K Dupuis Antimicrobial agents and chemotherapy 47 (2), 475-479, 2003 | 97 | 2003 |
| The Candida albicans Lanosterol 14-α-Demethylase (ERG11) Gene Promoter Is Maximally Induced after Prolonged Growth with Antifungal Drugs JL Song, JB Harry, RT Eastman, BG Oliver, TC White Antimicrobial agents and chemotherapy 48 (4), 1136-1144, 2004 | 91 | 2004 |
| Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum RT Eastman, J White, O Hucke, K Bauer, K Yokoyama, L Nallan, ... Journal of Biological Chemistry 280 (14), 13554-13559, 2005 | 89 | 2005 |
| Drug repurposing screen for compounds inhibiting the cytopathic effect of SARS-CoV-2 CZ Chen, P Shinn, Z Itkin, RT Eastman, R Bostwick, L Rasmussen, ... Frontiers in Pharmacology 11, 592737, 2021 | 87 | 2021 |
| Synergistic and antagonistic drug combinations against SARS-CoV-2 T Bobrowski, L Chen, RT Eastman, Z Itkin, P Shinn, CZ Chen, H Guo, ... Molecular Therapy 29 (2), 873-885, 2021 | 85 | 2021 |
| An OpenData portal to share COVID-19 drug repurposing data in real time KR Brimacombe, T Zhao, RT Eastman, X Hu, K Wang, M Backus, ... BioRxiv, 2020 | 77 | 2020 |
| Targeting ACE2–RBD interaction as a platform for COVID-19 therapeutics: development and drug-repurposing screen of an AlphaLISA proximity assay QM Hanson, KM Wilson, M Shen, Z Itkin, RT Eastman, P Shinn, MD Hall ACS Pharmacology & Translational Science 3 (6), 1352-1360, 2020 | 76 | 2020 |
| Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents J Ohkanda, FS Buckner, JW Lockman, K Yokoyama, D Carrico, ... Journal of medicinal chemistry 47 (2), 432-445, 2004 | 72 | 2004 |
David FidockProfessor of Microbiology & Immunology and of Medical Sciences (in Medicine), Columbia University在 columbia.edu 的电子邮件经过验证
